Listed in Current Contents as one of 1000 most quoted scientists 1981Paper listed as Citation Classic by Current Contents 1984 Philip S Hench Distinguished Alumnus Award U Pittsburgh School of Medicine 1988 Distinguished Scientist Award International Academy of Tumor Marker Oncology 1998Gary J Miller Memorial Award for excellence in teaching AACR 2002 Rudolph L K Virchow Award LeadershipMedica ITALY 2005 Legacy Laureate University of Pittsburgh Highest Honor for Alumni 2005 Paper cited as Scientific Landmark in Cancer Research by the American Association for Cancer Research 2007Abbott Award of the International Society for Oncodevelopmental Biology and Medicine 2007Keynote Speaker International Academy of PatholAogy Athens Greece 2008

Cancer: To determine how bone marrow derived mesenchymal stem cells influence the development of cancers in other tissues.,Cancer: To block proliferation of breast cancer stem cells by small molecular inhibitors or inhibitory RNA. This is a critical step to preventing re-growth of breast cancer after chemotherapy or radiation therapy. ,Carcinogenesis: To study the metabolism of aflatoxin and development of liver cancer in mice lacking glutathionine-S-transferase.,Aging: To compare the ability of young vs. old bone marrow derived stem cells to reconstitute and provide long term survival after lethal irradiation and transplantation, and the ability of wild-type bone marrow to prolong life of early aging mice.

Medical education; Karolinska Institute 197076 Clinical education; Karolinska Hospital Stockholm Oncology South Hospital Stockholm Hematology Appalachian Regional Hospital West Virginia USA Surgery Outpatient Clinics Mora Malung Internal medicine Primary care University Hospital Lund Oncologyspecialty training 1978831983 Board certified in Oncology 1984 PhD Oncology 1989 docent 1990 senior lecturer Oncology 1995 head physician Oncology 1996 Professor Oncology Swedish title: bitr professor i onkologi 1999 Professor Oncology Swedish title: professor i tumörsjukdomar

Cancer genetics, environmental and genetic risk factors of malignant diseases especially: malignant lymphoma, melanoma, breast cancer, sarcoma, testicular cancer, prostate cancer and ovarian cancer. BRCA1, BRCA2 and p53 associated tumour disease . Genetic predisposition. Hormonal carcinogenesis. Environmental carcinogenic exposures.

DR JAROSLAVA HALPER is a professor in the Department of Pathology College of Veterinary Medicine The University of Georgia Athens Georgia She has received her MD from the University of Toronto in 1980 and a PhD in Experimental Pathology from the University of Minnesota at Mayo Clinic in 1986 She trained in Pathology at Albert Einstein College of Medicine in the Bronx NY and at the Mayo Clinic in Rochester MN board certification in 1984 She characterized transforming growth factor e TGFe the first member of the granulin family to be identified Her laboratory has shown that TGFß4 an isoform thought to be specific to avian speciesis actually TGFß1

Role of growth factors in carcinogenesis and tissue repair. More recently she has been working on biochemistry and pathology of tendons. Her studies on pathogenesis of so called degenerative suspensory ligament desmitis in horses represent a breakthrough in current knowledge of this devastating disease.

Prof Claudio Luparello PhD in Cell Biology is a Full Professor of Cytology and Histology at the University of Palermo Italy He has authored more than 40 publications and 3 book chapters and was the Editor of the book “Novel aspects in PTHrP physiopatology” edited by Nova Sci Pub He serves in the Editorial Board of Biological Procedure Online International Journal of Breast Cancer and TheScientificWorldJournal domains Cell Biology and OncologyHe is a member of AICC

Human mesenchymal stem cells, osteogenesis, adipogenesis, molecular markers, breast cancer cells, invasion, proliferation, apoptosis, gene expression, PTHrP, collagen, extracellular matrix

Joined the staff of Roswell Park Cancer Institute RPCI in 1994 as Clinician Division of Leukemia Department of Medicine He earned his medical degree from the Hebrew University Hadassah Medical School Jerusalem Israel in 1980 and completed residency training in Internal Medicine at Kaplan Hospital affiliated with Hebrew University Hadassah Medical School Rehovot Israel in 1986 From 1988 to 1992 he completed fellowships in Clinical Immunology and Biologic Therapy and in Medical Oncology at MD Anderson Cancer Center Houston TXCoauthored more than 100 journal publications book chapters and abstracts He serves as Journal Referee for Blood Cancer Stem Cells Leukemia Research and the Journal of Clinical Oncology

Role of signal transducer and activation of transcription in leukemogenesis.The cellular and humoral immune response to leukemic-associated antigens.Cytogenetics in acute myeloid leukemia (AML).Acute lymphoblastic leukemia (ALL).

Reorganization of a pediatric department and navigating it from a state of crisis to stability and renewed productivity and developmentLeading the development of new Pediatric programsEstablishing a new Pediatric Clinical Trial enterprise within the department of pediatricsRepresenting the department of pediatrics at the higher levels of the hospital leadershipActive participation as a physician champion in the successful implementation of a new EMR systemActive member of multiple hospitalwide quality improvement projects

Cancer

The goal of this proposal is to determine the mechanism by which topical application of the opioid antagonist naltrexone accelerates the healing of skin wounds in Type 1 diabetic mice The basis of this proposal stems from our long time expertise in opioids cell proliferation wound healing and diabetes In 1983 using a paradigm of intermittent and continuous opioid receptor blockade with naltrexone NTX we Drs Zagon and McLaughlin discovered that endogenous opioids and opioid receptors previously thought to be related only to neural cells and neurotransmission serve as determinants of cell proliferation This has led us on a journey of discovering the opioid peptide [Met5]

One direction of our research has been to understand the role of opioids in diabetes. It is well known that diabetics have an elevate level of enkephalins and problems with pain perception. We have connected the increased levels of opioids with delays in wound healing commonly occurring in diabetics. In grants sponsored by NIDDK, we have found that a topical application of NTX accelerates corneal wound healing in animals with Type 1 diabetes by disrupting the enhanced interactions of the OGF-OGFr axis in these animals. Introduction of sense or antisense of OGFr into the cornea by a gene gun revealed that the OGF-OGFr pathway is vital to regulating cell proliferation and wound healing. In the course of these experiments, we have devised a topical application of a cream of NTX that accelerates the closure of skin wounds in diabetics. NTX is known as a pure biological compound with little to no direct effects, and we hypothesize that NTX is accelerating wound healing of skin by blocking a critical opioid peptide-opioid receptor pathway. This grant application seeks to understand the underlying basis for these phenomena and tests our hypothesis in mice with Type 1 diabetes by employing knockout animals for classical and non-classical (OGFr) receptors and studying the absence of receptors on wound healing. In a third specific aim, we will use tissue culture of epithelial cells along with a wound model to integrate information in Specific Aims 1 and 2 with the cell and molecular biology of opioid action. In summary, we have pioneered in the use of NTX to upregulate wound healing, developed a topical NTX that is safe and efficacious for skin wound repair, have the reagents, tools, and experience to conduct the [-enkephalin - termed opioid growth factor (OGF) in view of its non-neural and neural distribution as well as its function in growth), and opioid receptor (OGFr) associated with cell proliferation. We have partnered with clinicians to translate our science from bench to bedside, and clinical trials have been published regarding the use of OGF - and low dose naltrexone (LDN) - for the treatment of cancer and autoimmune diseases showing safety and efficacy, and topical application of NTX is now being examined in a clinical trial sponsored by the Department of Defense by my co-investigator, Dr. Joseph Sassani. proposed research, demonstrated a record of successful and productive research projects in an area of high relevance to human health and disease, and we are addressing an important unmet medical needs.

Susan Marriott is a Professor of Virology and Microbiology at Baylor College of Medicine in Houston Texas She earned her PhD at Kansas State University studying viral replication under the mentorship of Richard A Consigli She subsequently carried out postdoctoral training at the National Institutes of Health in Bethesda MD in the lab of John N Brady where she began to study the mechanism of cellular transformation mediated by retroviruses She joined the faculty at Baylor College of Medicine in 1991 and has developed an active research program focusing on the role of genomic instability in human retroviral transformation Over the years she has participated as a member of numerous grant review panels for the National Institutes of Health and the American Cancer Society has been an invited speaker at national and international conferences and has published extensively on viral carcinogenesis

Human T-cell leukemia virus type I (HTLV-I) was the first retrovirus shown to cause cancer in humans. The major viral oncoprotein, Tax, is a transcriptional regulator of viral and cellular gene expression, and interacts with many important cellular proteins that regulate cell cycle progression, and cellular responses to DNA damage. The ongoing studies in my lab encompass a broad-based effort to understand the molecular mechanisms of Tax function, and how these functions promote genomic instability and cellular transformation.

Frederick Domann is a Professor of Radiation Oncology in the Free Radical Radiation Biology Program at The University of Iowa in Iowa City Iowa USA He earned his PhD at the University of WisconsinMadison in Human Cancer Biology under the mentorship of Kelly H Clifton and subsequently carried out postdoctoral research at The Arizona Cancer Center with G Tim Bowden He joined the faculty at The University of Iowa in 1993 and has since become an internationally recognized expert in and free radical biology and cancer

Transcriptional regulation ,Free radical biology ,Metabolism ,Epigenetic control of gene expression in human cancer.

Emanuela Taioli MD PhD is Professor of the Department of Epidemiology and Biostatistics and Professor of Hematology and Oncology within the School of Medicine at SUNY Downstate From 2005 to 2008 she was Director of the Division of Cancer Prevention and Population Science at the University of Pittsburgh Cancer Institute where she also held the Arnold Palmer Endowed Chair in cancer Prevention In this capacity she has developed a successful partnership with Hampton University under NIH funding to teach Epidemiology to undergraduate students From 20022004 Dr Taioli was a technical advisor to the Italian Ministry of Health In this role she served as a member of the European High Group of Reflection on Patients Mobility Previously Dr Taioli was Director of the Unit of Molecular and Genetic Epidemiology at the main University Hospital in Milano Italy and the PI of the GSEC project an International Study on Genetic Susceptibility to Environmental Carcinogens Started in 1997 and funded by the European Commission for Research GSEC is a pooled analysis of individual epidemiologic and genetic data including over 200000 subjects Dr Taioli was also an assistant professor in the Department of Environmental Medicine at New York University In this role she conducted studies on genetic susceptibility to environmental factors in lung and breast cancer and differences in estrogen metabolism with ethnicity in womenDr Taioli obtained her Medical Degree from the University of Milano where she also completed her Residency in Cardiology She obtained an MS and a PhD in Epidemiology from Columbia University Dr Taioli also worked under a NATO fellowship at the American Health Foundation in New YorkDr Taioli is also the coauthor of over 260 peer reviewed papers

Epidemiology,Molecular Epidemiology, Cancer risk factors, tobacco, hormone metabolite, melatonin, gene-environment interaction, epigenetics,

Director Maine Center for Toxicology and Environmental Health University of Southern Maine Professor of Toxicology and Molecular Epidemiology University of Southern Maine Director of Toxicology Ocean AllianceBoard Member Friends of Casco BayAdjunct Professor of Biology University of Southern Maine Adjunct Professor of Pharmacology University of New England Member Graduate Faculty University of MaineResearch Fellow Edgerton Research Laboratory New England Aquarium Adjunct Researcher Mystic Aquarium and Sea Foundation Lead Guest Editor Journal of ToxicologyEditorial Board Member Journal of Carcinogenesis Mutagenesis Editorial Board Member Journal of Ecosystem EcographySecretary/Treasurer Metals Specialty SectionSociety of Toxicology Editorial Board Member The Open Toxicology JournalMember State of Maine’s Medical Advisory Committee for The Maine Board of Pesticides Contro Member Maine Innovation Economy Advisory BoardMember Gulf of Maine Council’s Ecosystem Indicator Partnership ESIP contaminants group Associate Editor Life Sciences Member Program Committee Environmental Mutagen Society Member State of Maine Environmental Risk Advisory Committee Member Maine Biological and Medical Sciences Symposium Member Maine State Department of Environmental Protection’s Surface Water Ambient Toxics monitoring program

Carcinogenesis & Muatgenesis

Kandace Williams is a Professor in the Department of Biochemistry Cancer Biology at the University of Toledo College of Medicine UTCOM; formerly Medical College of Ohio where she has been since 2001 She was formerly a faculty member at the University of Alaska Biomedical Program Her postdoctoral fellowship was with Dr Lawrence Loeb in the Department of Pathology at the University of Washington School of Medicine She is currently affiliate faculty in the Department of Pathology She received her PhD from the Department of Pharmacology and Toxicology at Dartmouth Medical School and her BS Cum Laude at the University of Alaska Anchorage She has served on the NIH Cancer Etiology and Chemical Pathology study sections for several years is on the Editorial Board of Mutation Research and a Board member of American Society for Circumpolar Health as well as Council member of the Environmental Mutagen Society She also serves on the UTCOM Institutional Review Board for Human Research Cancer Biology PhD Program Steering Committee Cancer Center Steering Committee Cancer Center Program Director Cell Biology and Pathogenesis section and the Research Advisory Committee for the Dean

Mechanisms of DNA damage and repair of alkylating agents.Base excision and mismatch repair within different phases of the cell cycle. Mismatch repair-induced DNA damage response and cell cycle effects.DNA damage response effects on replication factories.

Dr Yuesheng Zhang is currently a Professor of Oncology at Roswell Park Cancer Institute RPCI He earned his MD from Zhejiang University School of Medicine in China and His PhD in Pharmacology and Molecular Sciences from Johns Hopkins University School of Medicine in USA He also completed his postdoctoral fellowship at Johns Hopkins University Dr Zhang currently works in the field of cancer chemoprevention particularly bladder cancer chemoprevention

Oncology

Professor in Florida International University, Department of Environmetal & Occupational Health

Environmental Oncology

Dr Yi Sun received his medical training in Jiangxi Medical College P R China He came to the USA in 1986 and obtained his PhD at the University of Iowa in 1989 He then spent 5 years at the NCI first as a postdoctoral fellow then as a senior staff fellow He was recruited to ParkeDavis/Warner Lambert in 1995 and spent 8 years in pharmaceutical industry He joined the faculty at Department of Radiation Oncology University of Michigan in 2003 as an associate professor and became a professor and director of Division of Radiation and Cancer Biology in 2008 Dr Sun has published 145 peer reviewed articles and is an internationally recognized expert in protein ubiquitination and degradation and p53 pathway regulation

SCF E3 ubiquitin ligase in regulation of apoptosis, angiogenesis, and carcingenesis Anticancer and radiosensitizing activity of E3 ubiquitin ligase inhibitors P53 and its signal pathway in regulation of apoptosis, senescence, and autophagy Drug discovery targeting p53 and p53 pathways.

Dr Cheng is a Professor in the Department of Pharmacology and Toxicology at the University of Texas Medical Branch UTMB and Deputy Director of the NIEHSfunded Center in Environmental Toxicology at UTMB He is also a member of the Sealy Center of Cancer Cell Biology Sealy Center of Structural Biology and Molecular Biophysics and Center for Addiction Research He received his PhD in Biochemistry and Molecular Biology at the University of Texas Medical Branch in 1994 and completed a postdoctoral fellowship in biochemistry under Professor Susan Taylor from University of California in San Diego in 1999 Dr Cheng is a recipient of an American Cancer Society Research Scholar Award He also received the HUPO 3rd World Congress Young Scientist Award in 2004 Dr Cheng currently serves as an Editor for Acta Biochimica et Biophysica Sinica and is on the Editorial Boards of Frontiers in Bioscience and The Open Proteomics Journal

Dr. Cheng’s research program focuses on using multidisciplinary approaches, coupling biochemistry and biophysics with cell biology and pharmacology, to understand the structure and function of exchange protein directly activated by cAMP (Epac) and oncogene KRAS. Our long-term goals are to unravel the signaling intricacies of Epac and KRAS and to design pathway specific inhibitors for these important signaling molecules so that their functions can be pharmaceutically exploited and modulated for the treatment of human diseases.

Dr Watabe is a Professor in the Department of Medical Microbiology Immunology and Cell Biology at Southern Illinois University School of Medicine He received his PhD from Kyoto University in 1981 and did postdoctoral training at the University of Arizona Health Science Center He then joined Southern Illinois University as a faculty member in 1985 He also served as Associate Director of Basic Science at SIU Cancer Institute His current research focuses are tumor metastasis cancer stem cells and tumor microenvironment He has served on many national and international grant review panels including NIH and DOD and is on the editorial boards of several international journals

Tumor metastasis suppressor genes,Prostate and breast cancer pathology,Cancer stem cell in microenvironment,Tumor cell dormancy and recurrence,Nutrition and cancer progression

Wai Y Tan is a tenured Research Professor in the Department of Mathematical Sciences at the University of Memphis Memphis TN 38152 During 1984–1985 he had served as a Cancer Expert at National Cancer Inst National Inst of Health Bethesda MD; during 1990 a Visiting Prof in the Dept of Epidemiology Biostat Emory Univ School of Med Atlanta GA and a Mathematical Statistician in the Div of HIV/AIDS Centers for Disease Control Atlanta GA During 19951996 he has also served as a Guest Researcher National Cancer Institute/NIH Bethesda MD Dr Tan received a PhD in mathematical statistics from University of Wisconsin Madison Wisconsin in 1964 and a MS in mathematics in 1963 In 1983 and 1989 he has received distinguished research awards by Memphis State University Memphis TN and in 1984 1988 19901994 1995 Spur Award for research by Memphis State University Memphis TN In 1995 he was elected ASA fellow by the American Statistical Association for contributions to statistical methodology and to stochastic modeling of cancer In 1997 he was elected member by the International Statistical Institute Since 1989 he has served as a member of numerous study sections at least 20 for NIH AIDS grants and cancer grants He has served as a Peer Review Member of the Special Comm for Center for AIDS Research NIAID/NIH and a Peer Review member of the Special Committee of NCI/NIH for RFA grant applications “Centers of Cancer nanotechnology Excellence� During 19992001 he served as a Member of the Advisory Board of Academia Sinica Taiwan ROC and during 19992001 an Outside Reviewer of the Medical research Council Biostatistics Unit of Cambridge University Cambridge England Dr Tan has served as a member of the Editorial board of Biology Direct and has reviewed papers for most of the important biomathematical statistical and biostatistical journals as well as Nature methods

Dr. Tan has published 8 books and over 210 research papers and book chapters covering a wide range of topics of probability and statistics including Bayesian inferences, robust inferences, multivariate analysis, mathematical genetics, biostatistics, stochastic modeling of cancer, AIDS, HIV pathogenesis, cancer biostatistics and cancer risk assessment of environmental agents. His current research interests are mainly in the following areas: (1)Cancer stochastic models,(2) Cancer biostatistics,(3)Cancer risk assessment, (4) Cancer genetics, (5) Stochastic models for cancer, AIDS and infectious diseases

Dr Cunningham is the Director of the Genotyping Shared Resource GSR in the Advanced Genomic Technology Centre Mayo Clinic College of Medicine in Rochester Minnesota USA Dr Cunningham has directed the activities of this shared resource since 2004 charged at that time to bring the facility to a high throughput facility using cutting edge technology The GSR supports genomic studies of Mayo Clinic investigators their collaborators and outside investigators The laboratory provides genome wide genotyping for gene association and linkage based analyses targeted genotyping for SNPs and insertion/deletion polymorphisms epigenetic analyses and array CGH Studies both large and small may be accommodated; over 12000 GWAS samples were run in 2010 The GSR has contributed genotyping for several consortia including the Ovarian Cancer Association Consortia OCAC and Consortium of Investigators of Modifiers of BRCA1/2 CIMBA and is contributing to the genotyping of 40000 samples using the Illumina Collaborative Oncological Geneenvironment Study iCOGS custom Infinium SNP array The GSR is a collaborative entity with expertise in genomics supporting several multimillion US grants during 2010The mission of the GSR is a continued commitment to provide the highest quality genotyping data using advanced technology to enhance the understanding of human disease improve health and promote excellence in patient care

My research work relates to elucidation of the genetic basis of disease. My primary focus is the genetic basis of familial cancer, in particular, cancers of the colon, prostate, ovary, NHL and CLL, breast and pancreas. As director of the Genotyping Shared Resource, I also participate in a number of research projects including Parkinson’s Disease, Vaccine Research, Addiction and Pharmacogenetics. I work closely with individuals from biostatistics, epidemiology, and the Mayo Clinic Cancer and Genomics Centers

Director of Research AffairsDepartment of Internal MedicineUniversity of North Dakota School of Medicine and Health Sciences

Cancer Science

David L McCormick is Senior VicePresident and Director of IIT Research Institute and Professor of Biology at Illinois Institute of Technology Chicago Illinois A boardcertified toxicologist Dr McCormick’s primary research activities are in the areas of carcinogenesis and cancer prevention nonclinical toxicology and the biological effects of magnetic fields He has served as Principal Investigator on approximately 50 grants and contracts funded by the National Cancer Institute and the National Institute of Environmental Health Sciences with total funding of more than 80000000 Dr McCormick has also worked in preclinical drug development programs with numerous sponsors in the pharmaceutical and biotechnology industries He has published more than 250 research papers abstracts and reviews Dr McCormick received his AB degree in Biology/Chemistry from Middlebury College and his MS and PhD degrees in Environmental Medicine/Biology from New York University

Cancer Chemoprevention ,Nutrition and Cancer,Preclinical Drug Development,Animal Carcinogenesis Models,Biological Effects of Non-Ionizing Radiation (magnetic fields)

Dr Wang is the Director of Proteomics and an Associate Professor of Biochemistry and Molecular Biology at the Indiana University School of Medicine He earned his PhD in BioOrganic Chemistry from Washington University in St Louis Missouri and was an NIH/NRSA postdoctoral fellow studying mechanisms of DNA repair in mammalian system He joined the staff of Indiana University School of Medicine in 2001 as the Scientific Director of Proteomics and established a Proteomics Core Facility His expertise includes 2DE and LC/MSbased proteomics DNA repair surface plasmon resonance and cancer drug resistance He has supervised many graduate students postdoctoral fellows and research associates He is also a CoPrincipal Investigator on the National Cancer Institute’s Clinical Proteomics Technologies for Cancer Program and has worked with many clinical investigators worldwide He received a number of awards including a Young Investigator’s Award in 2004 HUPO meeting He has published more than 60 peerreviewed articles in DNA repair biochemistry and proteomics related journals and served as a reviewer for many journals as well as NIH and Department of Defense grant applications

Molecular Mechanisms of DNA Damage and Repair,Cancer Biomarker Development including Early Detection for Breast Cancer and Ovarian Cancer, Drug Targets for Platinum Resistance, and Prognostic Signatures for Ataxia-Telangiectasia , New Methodology Development for Targeted Protein Assays and Small-Molecule/siRNA Drug Delivery

Is Chief of the Carcinogenesis Branch Integrated Systems Toxicology Division National Health and Environmental Effects Research Laboratory U S Environmental Protection Agency Research Triangle Park NCHe received a BS in Biochemistry from the University of Dallas Irving Texas 1977He received a PhD in Biology from the University of Texas at Dallas Richardson Texas 1982He received a John B Omiddot;Hara Undergraduate Chemistry Research Fellowship a Robert A Welch Foundation Predoctoral Fellowship and a National Academy of Sciences National Research Council Postdoctoral Fellowship He is the recipient of multiple Scientific and Technological Achievement Awards from the U S Environmental Protection Agency as well as a Bronze Medal for Commendable Service He is a former President of the Genetics and Environmental Mutagenesis SocietyHe has served as a peer reviewer for 11 scientific journals

Chemical Carcinogenesis,DNA adduct formation and repair,Mutagenesis,Predictive omarkers,Toxicity pathways

Research Assistant Department of Oncology Middlesex Hospital London Research Associate Department of Oncology Middlesex Hospital London Head of Molecular Genetics Laboratory Marie Curie Research Institute Oxted SurreyProfessor or Experimental Cancer Research University of LeedsAssociate Director Laboratories Cancer Research UK Clinical Centre Leeds

Molecular genetics, bladder cancer, FGF receptors, PI3K pathway signalling

Ken Raj Ken Raj is a Senior Scientific Group Leader at the Health Protection Agency Didcot Chilton Oxfordshire United Kingdom He received his MSc and PhD in Cancer Virology from the University of Cambridge 1990 1994 He completed his postdoctoral training at the Swiss Institute for Experimental Cancer Research at Epalinges Lausanne Switzerland 19952003 He led his first research group at the National Institute for Medical Research NIMR of the Medical Research Council Mill Hill London United Kingdom 20032009

Virology and Radiobiology in relation to Cancer,Radiobiology in relation to Cardiovascular Disease,Radiobiology in relation to stem cells

Recent Patent Reviews on AntiCancer Drug Discovery International Journal of Clinical Oncology Recent Patents on AntiInfective Drug DiscoveryOpen Journal of Hematology

Chemotherapy and bone marrow transplantation of leukemia and related disease, Molecular targeting therapy, Immunocellular therapy, Drug resistance and its overcome, Stem cell biology, Signal transduction.

Visiting Associate Boston Consulting GroupDepartment of Surgery University hospital Dresden Group leader pancreatic surgery University hospital Dresden Professor of Surgery University hospital Dresden ~60 scientific publications in peer reviewed journals Extrabudgetary funding by DFG Deutsche Krebshilfe vonLangenbeckPreis der Deutschen Gesellschaft für Chirurgie 2005 Young Investigator Award: 11th Meeting of the International Association of Pancreatology and the 35th Annual Meeting of the Japan Pancreas Society 2004 Sendai JapanCancer Detection and Prevention;European Journal of Cancer; Oncogene; Annals of Surgery Associazione Italiana per la Ricerca sul Cancro

Development of new concepts for diagnosis and therapy of ductal pancreatic adenocarcinoma

Dr Marc DE BRAEKELEER is professor in the Department of Histology Cytology and Cytogenetics at the Faculty of Medicine and Health Sciences the University of Brest France and biologist in the Department of Cytogenetics Cytology and Reproductive Biology at the University Hospital of Brest He has received his MD from the University of Brussels Belgium in 1975 and a PhD in Genetic Epidemiology from the University of Bordeaux France in 1995 He trained in cytogenetics at the University of Calgary Alberta Canada and at the University of Alberta in Edmonton AlbertaHe has coauthored more than 150 journal publications and book chapters He serves as referee for several cancer and genetics journals

Cyogenetics and molecular genetics in acute myeloid leukemia, acute lymphoblastic leukemia and myelodysplastic disorders

Philippe Becuwe is a professor of cellular and molecular biology in Henri Poincaré’s University of Nancy He received a PhD in Biology and Health 1994 from the Lille University Lille France He is professor since 2007 and is a manager of a research team in his cancer research unit He has authored 35 peerreviewed articles and among them some invited review articles He is serving as a reviewer in several international journals

Molecular and cellular biology of cancer,Discovery of new predictive factors of the breast tumor progression and response to anticancer drugs,Transcriptional regulation, genomic and post-genomic,Free radical biology and antioxidant enzymes, metabolism.

Featured in Marquis Who’s Who in the World since 18th edition 2001 by invitationFeatured in Marquis Who’s Who in Medicine and Healthcare since 4th edition 2003 by invitationFeatured in Marquis Who’s Who in Science and Engineering since 6th edition 20022003 by invitation wwwwikipediade

Oncology

Javier S Castresana is a Professor of Genetics at the University of Navarra School of Sciences in Pamplona Spain He received a MD 1987 and a PhD 1992 from the University of the Basque Country Leioa Spain He was a research fellow at the Karolinska Institute Stockholm Sweden 19881990 and at the Massachusetts General Hospital and Harvard Medical School Boston USA 19901992 He joined the Spanish Research Council CSIC in Madrid 19921997 as a senior scientist and finally moved to the University of Navarra as an Assistant Professor 19972004 Associate Professor 20042010 and Professor of Genetics where he directs the Brain Tumor Biology Unit and dedicates to understanding the molecular genetics and cell biology of lethal tumors like glioblastoma medulloblastoma and neuroblastoma He has published more than 65 articles in scientific journals more than 10 book chapters in oncology and more than 100 communications to scientific meetings He has directed about 16 Ph theses He acts as a reviewer of more than 20 scientific journals in the oncology and pathology fields and of research projects at the European Commission and at several Spanish research agencies He teaches cancer genetics to Master’s students at the University of Navarra He is married and has 6 children

Cancer molecular genetics and cell biology of brain tumors, with an emphasis on glioblastoma, medulloblastoma and neuroblastoma.Cell cycle control in cancer.Genetic regulation of pathways related to development and cancer.Cancer stem cells.Molecular cytogenetics.

Cancer Therapy since 2004 The Open Enzyme Inhibition Journal since 2008 The Open Bioactive Compounds Journal since 2008 Gastrointestinal Cancer Review Letters since 2009 Liver Cancer Review Letters since 2009 World Journal of Hepatology since 2010 Annals of Hepatology since 2010 World Journal of Gastrointestinal Pharmacology and Therapeutics since 2010

Cancer

Andre van Wijnen studied biochemistry molecular biology cell biology and biomedical sciences at the University of Utrecht Netherlands the University of Massachusetts Worcester Massachusetts and the University of Florida Gainesville Florida He is currently a Professor at UMass Medical School in the Department of Cell Biology

Include cancer biology, bone biology and stem cell biology with a broad focus on cell cycle regulation and self-renewal, lineage-commitment and reprogramming, cell signaling and gene regulation, chromatin, epigenetics, microRNAs, as well as genomics and proteomics.

Since the late 1970’s the main research interest has been focused on Human papillomavirus HPV and its different manifestations in the human The majority of the scientific publications and the three major textbooks all listed above are dealing with HPVassociated human pathology This is the field in which Prof Syrjänen is a recognized world authority

Other current research interests include colorectal cancer (CRC) which is another main topic of research in our clinic. Included in the list of scientific contributions are also some 70 papers on female breast cancer, which is another main topic of his research interest.

Antonio Russo received his MD from the University Medical School of Palermo Italy in 1982 His postgraduate specialty were Medical Oncology and Medical Genetic Since 2006 he is professor of Medical Oncology and Chief of the Medical Genetic and Molecular Oncology Unit at University Medical School of Palermo Since 2004 he is Adjunct Associate Professor at Temple University College of Science and Technology Philadelphia USA In 2001 he coordinated with Prof D Kerr University of Oxford UK and Prof B Iacopetta Western Australia University the “CRCP53 International Collaborative Study” Since 2003 he is Expert member of INSERM Institut National de la Santè et de la Recherche Mèdical France Since 2007 he is Expert member of the INCA Institut National du Cancer France Scientific Committee and Expert member of NWCRF North West Cancer Research Fund UK He has been Guest Editor of the following toprated journals: Annals of Oncology Oncology and Cancer Treatment Reviews The central theme of his studies is translational research meaning the application of molecular genetics in the diagnosis and treatment of solid malignancies He is author of more than 200 publications in toprated cancer journal and serves as Journal Referee for the following journals: Cancer Gastroenterology Cancer Research Human Pathology Clinical Cancer Research Oncogene J of Pathology Annals of Oncology British J of Cancer Critical Reviews in Oncology/Hematology and Cancer Biology Therapy

Prognostic and predictive biomolecular markers.Molecular genetics of hereditary and familial tumors, especially those of the breast/ovarian and of the gastroenteric tract Detection of tumor cells in peripheral blood and lymph nodes of patients with solid tumors. Analysis of gene expression by microarray in solid tumors. Role of the MicroRNA and epigenetic profile in solid tumors.

Since the late 1970’s the main research interest has been focused on Human papillomavirus HPV and its different manifestations in the human The majority of the scientific publications and the three major textbooks all listed above are dealing with HPVassociated human pathology This is the field in which Prof Syrjänen is a recognized world authority

Other current research interests include colorectal cancer (CRC) which is another main topic of research in our clinic. Included in the list of scientific contributions are also some 70 papers on female breast cancer, which is another main topic of his research interest.

Dr Daneri is a Professor in the Department of Physiology at the University of Guadalajara He has received his MD from the University of Guadalajara in 1982 and the PhD in Basic Biomedical Research Tumor Biology and Immunology from The National Autonomous University of Mexico in 1995 He has described tumor evasion mechanisms induced by cervical cancer cells and HPV He studied the role of proteases dendritic cells and NK cells in cervical cancer oncogenesis and progression from squamous intraepithelial lesions SIL linked to HPV infection Dr Daneri’s group reported the loss of CEACAM1 adhesion molecule with tumor suppressor function in invasive cervical cancer Adrian DaneriNavarro is member of the Steering Committee of United StatesLatin America Cancer Research NetworkNCI and is serving as reviewer of cancer and immunology journals

Tumor evasion mechanisms induced by tumor cells and viruses. Immunological and molecular factors involved in SIL recurrence post-treatment and cervical cancer progression. Breast and cervical cancer molecular profiles and genetic alterations with the aim to find new prognostic and prediction factors in Hispanic population.

Professor Rocio IR Macias born in Erlangen Germany in 1968 received her PhD in Pharmacy from the University of Salamanca Spain in 1996 following which she continued her training in Pathophysiology as Postdoctoral Fellow at the University of Zurich Switzerland 1999 and at the Immunology Department National Health Institute Carlos III Majadahonda Spain and during sabbatical stages at the Universities of Paris 2004 and Düsseldorf 2007 In 2008 Dr Macias got a Professor position in Physiology at the University of Salamanca She has actively participated in the predoctoral and postdoctoral education of more than 20 young scientists During the last decade she has been interested in the investigation of pharmacological strategies to overcome resistance to chemotherapy and improve targeting of anticancer drugs towards tumors of the enterohepatic circuit She has contributed with more than 50 in internationals journals eg Hepatology Journal of Hepatology Biochemical Journal International Journal of Cancer Molecular Pharmacology American Journal of Physiology Journal of Pharmacology and Experimental Therapeutics

Cancer

The University of Rome “La Sapienza� Rome Italy 1985 Board Certified in Hematology 1989 and Internal Medicine 1995 Attending Physician Emergency Medicine Department of Medicine Viterbo and Civita Castellana Hospital 19891991 Fellow Experimental Immunology Branch NCI NIH Bethesda MD 19931997 Research Fellow FTE Allogeneic Heatopoietic Stem Cell Transplantation Hematology Branch NHLBI NIH Bethesda MD 20012004 Junior Faculty Department of Immunology Roswell Park Cancer Institute Buffalo NY 20042005 Currently Investigator i/e Assistant Member Institute of Translational Pharmacology Department of Medicine National Council Research CNR Rome Italy Contract Professor Oncology Department of Surgery University of Rome�Tor Vergata� 20072010 Medical and Scientific Consultant Lazio regional Agency for Organ Transplantation

Innate Immunity, Monocyte/macrophage and NK cell biology, Optimization of allogeneic hematopoietic stem cell transplantation through cytotoxic cell immunotherapy, Mechanisms of malignant cell evasion from host immune surveillance, Clinico-pathological role of innate immunity in common epithelial malignancies and myeloid leukemias

19801996 – Research Associate Department of Molecular Genetics Institute of Genetics BAS; 1996 – continue Associated Professor Institute of Genetics Department of Molecular Genetics

Induction and repair of DNA and chromosomal damage in eukaryotic genome. Gene-specific repair. Genetic toxicology. Genome stability.

Graduated from the Nagoya University School of Medicine at 1975 Received PhD and MD from the same university at 1982 Became an associate professor in the Department of Immunology Nagoya University School of Medicine at 1982 From 1984 to 1986 working as a research fellow at London University Professor Av Mitchison and at the laboratory of Gene structure and expression in MRL London Dr F Grosveld At 1995 he became a head of laboratory of basic gerontology when National Institute for Longevity Sciences was set up From 2005 a professor of Department of Immunology Nagoya University School of Medicine

Immunology, Aging and Stem cells

MD School of Medicine University of Padua Italy 1983Postgraduate School of Oncology University of Padua Italy 1987Postgraduate School of Pharmacology University of Padua Italy 1991Visiting Professor in Oncology/Pharmacology for Biotechnology degree at the University of Trieste Visiting Professor of Molecular Pathology in the Oncology Specialization School� at the University of UdineVisiting Professor Nanotechnology School at the University of TriesteTeaching trainer Scientific Direction–CROAvianoPharmacology Science School Board University of Padua Ethical committee member CRO Aviano Hospital Pordenone Scientific Library Committee CRO Aviano Awarded 1st prize scientific innovation Start Cup competition Friuli Venezia Giulia – Italy 2009He is serving as an editorial board member of reputed journals and reviewer of 15 journals Number of publications reviewer for 70

Pharmacogenetics/pharmacogenomics,Immunogenetics, Phase I-II clinical trials,Pharmacokinetics,Theory and Practice of Informed Consent in Biomedical Research

Visiting Professor of Thoracic Oncology Yale University School of Medicine Yale Cancer Center CT USA 2006Present Consultant and Head Oncology Unit 3rd Dept of Medicine Sotiria General Hospital Athens Greece 2000Present Professor of Oncology in Medicine Athens University School of Medicine Athens Greece 2000Present Member of the Faculty and Greek Representative to The Vienna School of Clinical Research Vienna Austria 2006Present Assistant Professor of Oncology in Medicine Larissa Medical School Larissa Greece 19992000 Specialist Registrar Oncology Dept The Royal Hospital NHS Trust St Bartholomewrsquo;s Hospital University of London London UK 19971999 Registrar Senior Resident Dept of Clinical Oncology Hammersmith Hospital Campus Imperial College of Science Technology and Medicine London UK 19951997 Senior House Officer Resident in Medical Oncology Hammersmith Hospital Campus Imperial College of Science Technology and Medicine London UK 19931995 Senior House Officer Resident in Medicine First Dept in Medicine Laikon University Hospital Athens School of Medicine Athens Greece 19901993 Senior House Officer in Medicine Resident Dept of Medicine 251 Air Force VA Hospital Athens Greece 19891990

Cancer

Masamitsu Yamaguchi received his BS and MS degrees from Kobe University in 1977 and 1979 respectively and the PhD degree in medical science from Osaka University Japan in 1983 From 1983 to 1985 he was a Postdoctoral Fellow at the Department of Biological Chemistry at Harvard Medical School Between 1985 and 2001 he was a Researcher Senior Researcher and later Section Head in Aichi Cancer Center Research Institute Since 2001 he has been a Professor at the Department of Applied Biology and Insect Biomedical Research Center Kyoto Institute of Technology He is serving as an Editorial Board member of “Journal of Biomedicine and Biotechnology� and “American Journal of Cancer Research�

Eukaryotic DNA polymerases, Eukaryotic DNA replication, Transcription, Chromatin regulation, Drosophila model for human diseases

Following a BSc in Chemistry and Biology VD pursued a PhD in Biochemistry at the University of Western Ontario His interests in receptors and signalling lead him to pursue a postdoctoral position at the Wellcome Research Laboratories in Research Triangle Park NC with Drs Pedro Cuatrecasas and Steven Jacobs Returning to Canada he joined the Biomedical Research Centre at UBC in Vancouver to begin work on signalling via cytokine receptors Since joining UBC as a faculty member in the Dept of Medicine he has progressed through the ranks and is currently appointed as Professor He also serves as director of the UBC Experimental Medicine Graduate Program with almost 200 students under the supervision of faculty members in a variety of clinical departments

His research interests have focused on various aspects of signal transduction, with initial emphasis on how the PI 3-kinase pathway was involved in cell survival. This work has also been investigating the control of the life and death balance in cells via control of BCL-2 family proteins. More recently, a number of alternative functions of BCL-2 family proteins have been characterized, including involvement in regulation of cell cycle and involvement in DNA damage response. Being a basic researcher in a clinical department has offered opportunities for several collaborations with clinician-scientists, leading to projects in a diverse set areas including atherosclerosis, tendon damage, inflammation and fibrosis in the respiratory field, multiple sclerosis and of course, cancer.

Franco M Buonaguro born in 1952 in Santrsquo;Agata dei Goti Benevento Italy has been interested since his years at the Medical School on cell differentiation and transformation with several agents such as chemical physical and biological agents Since 1983 his activity has been focused on the role of viral agents in human cancers in particular on the role of DNA viruses such us Herpesvirus HCMV HHV8 EBV and Papillomavirus HPV in the etiopathogenesis of Kaposi’s sarcoma KS and in genital cancers respectively l Several studies have been performed also on HIV/AIDS and more recently an HIV Vaccine Program has been established Dr Buonaguro is Director of the Mol Biology and Viral Oncology Unit at the Natl Cancer Institute “Fond Pascale “ NapoliItaly He graduated cum laude in 1977 at the “Federico II� Medical School in Naples Italy where achieved the specialty in Endocrinology in 1982 and the Specialty in Microbiology and Virology in 1992 After a postdoctoral fellowship at the Department of Cell Biology Argonne National Laboratory Argonne IL USA 197981 a WHO Fellowship and research associate position at the Tumor Biology Program Fred Hutchinson Cancer Research Center Seattle WA USA 198386 he became an assistant member of the Experimental Oncology F – Viral Oncology at Natl Cancer Institute in Naples He was promoted associate member in 1991 and became full member in 2001 Dr Buonaguro dedicated a lot of energy for DevelopingCountries’ needs in particular he has been involved in a large International Programs on AIDS Research in Uganda one of the Countries most heavily hit by the epidemic developing and coordinating the ICSC World Lab East Africa AIDS Research Center at the Uganda Virus Research Institute UVRI Entebbe of which he has been coDirector since 1995 and Director since April 2001 He is member of the World Federation of Scientists since 1997 has served as WHO virology consultant in 1996 and 2003 Member of WHO/ UNAIDS Network for HIV isolation and Characterization since 1996; Member WHO HPV DNA International Collaborative Study Group since 2002; Member of the PanEuropean HPV Immunology Group 2008 Dr Buonaguro is Editor in chief of Infectious Agents and Cancer Managing Editor of Frontiers in Bioscience and Editorial Board Member of the Chinese Journal of Medicine Extended CV and publication list at wwwpublicationslistorg/fmbuonaguro

Cancer

He has received his MD and PhD in Biochemistry from the University of Granada Spain and completed his residency training in Clinical Biochemistry in Virgen de las Nieves University Hospital Granada He is Associate Professor in the Department of Biochemistry and Molecular Biology University of Malaga Spain He also obtained the following accreditations: European Clinical Chemist European Communities Confederation of Clinical Chemistry Accreditation in Human Genetic Spanish Association of Human Genetic and University Expert in Epidemiology and Clinical ResearchUniversity of Granada He is Director of Hospital Tumor Registry Marbella Spain and Member of the European Association of Cancer ResearchHe has served as Principal Investigator on 15 grants and he is author of 65 articles 10 books and present 130 papers at National and International Scientific Meetings He served as journal referee for: British Journal of Cancer European Journal of Surgical Oncology Neoplasia Tumor Biology Journal of Cellular and Molecular Medicine Investigational New Drugs Current Medical Chemistry Supportive Care in Cancer Patient Preference and Adherence eBooks from Bentham ScienceHe was honoured as a Visiting Professor in the Department of Pathology University of Miami USA and he has received 12 Awards from different Scientific Associations

Implication in tumorigenesis and regulation of apoptosis-related genes. Influence of tumor biology in the relationship between diagnostic delay and prognosis in cancer patients.Tumor immunology. Screen-detected breast cancer: differences in biology and survival.

Dr SongZe Ding is a Research Scientist in Graduate Center of Toxicology University of Kentucky Lexington Kentucky He has been an Assistant Professor in Division of Molecular Oncology Institute of Genetic Medicine Hokkaido University in Sapporo Japan and Assistant Professor in Henan Provincial Hospital in Zhengzhou ChinaDr Ding received his PhD degree in Department of Medicine Beijing Medical University in Beijing China in 1992 He has completed his Master of Medicine in Guangxi Medical University 1989 his Bachelor of Medicine from Henan University School of Medicine in China and trained as postdoctoral fellow at the University of Virginia Dr Ding’s research is focused on inflammation and cancer especially Helicobacter pylori infection induced gastric carcinogenesis He is serving as international journal reviewer for a number of reputed journals such as PLoS ONE Cancer Letter Trend in Microbiology Journal of Gastroenterology and Hepatology et al and has 23 publications

Inflammation and cancer,Bacteria (Helicobacter pylori) infection induced gastric pathophysiology and cancer,Metal-induced carcinogenesis,Oncogenic pathways in epithelial cancer, Oxidative stress and epithelial cell damage, H. pylori microbiology and immunology.

Cancer is a nondiscriminatory disease afflicting millions of Americans annually One hallmark trait of many cancer cells irrespective of tissue type is the ability of cancer cells to grow faster than normal cells RNA polymerase III RNA pol III is an enzyme complex that catalyzes the transcription of many of the small structural RNA molecules required for RNA processing U6 snRNA and translation tRNA Thus RNA pol III plays a key role in regulating the growth of a cell because it plays an important role in the regulation of protein synthesis and for a cell to grow or multiple proteins are needed RNA pol III products have been demonstrated to be specifically elevated in a variety of cancers Accurate initiation by RNA pol III requires a protein complex called TFIIIB implicating TFIIIBmediated transcription as an important determinant of the biosynthetic capacity of a cell TFIIIB is a target for repression by tumor suppressors proteins that inhibit cell growth and activation by oncogenes proteins that activate cell growth We are actively seeking to identify the mechanisms by which RNA pol III transcription becomes deregulated in breast cervical and prostate cancer Our long term goal is to use our findings to ultimately identify novel pharmacological targets for cancer drug development The tumor suppressor BRCA1 has been shown to be mutated in familiar breast cancer BRCA1 plays a role in DNA repair cell cycle regulation and programmed cell death apoptosis as well as other cellular activities My laboratory has recently demonstrated for the first time that BRCA1 inhibits RNA pol III transcription and we hypothesize that BRCA1 negatively regulates RNA pol III transcription through TFIIIB The longterm goal of this project is to elucidate the mechanisms by which BRCA1 regulates RNA pol III transcription through TFIIIBNutraceuticals and other naturally occurring pharmacologically active components have been gaining increasing popularity in the United States especially in medicine Scientists are trying to determine the molecular mechanisms of how these nutraceuticals work at the level of the cell One such compound is EGCG the major component of green tea Green tea has been demonstrated to inhibit the growth of a variety of cancer cells but the molecular mechanism of how EGCG inhibits cancer cell growth is not well established We do know that both EGCG and RNA pol III have the capacity to modulate cell proliferation Thus we hypothesized that EGCG could modulate RNA pol III transcription Our data demonstrates that EGCG can repress RNA pol III transcription in cervical prostate and breast carcinoma cells The long term goal of this project is to elucidate the molecular mechanisms governing the regulation of RNA pol III transcription by the green tea component EGCG to identify novel pharmacological targets for cancer therapy My laboratory is also examining the regulation of RNA pol III transcription by other bioactive compounds such as resveratrol red wine and genistein soy in cancer Through this research we hope to determine the mechanisms by which natural products inhibit cancer cell growth

Regulation of RNA polymerase III transcription in cancer cells by the tumor suppressor BRCA1.Regulation of RNA polymerase III transcription in breast and prostate cancer by the polyphenols EGCG (green tea), resveratrol (red wine) and genistein (soy).

The goal of the proposed research is to establish nanovectors as a gene/miRNA delivery platform to develop novel molecular therapies targeting cancer stem cells I have the expertise leadership and motivation necessary to successfully carry out the proposed work I have a broad background in cancer biology and nanobiotechnology with specific training and expertise in key research areas for this application including molecular cancer therapeutics microRNA nanovectors for gene delivery As a postdoctoral fellow at Stanford and Georgetown I carried out pioneer studies in designing novel nanovectors for tumortargeted gene delivery which eventually obtained multiple patents and FDAapproval for the firstinman clinical trials of nonviral targeted p53 gene therapy At the University of Michigan I expanded my research to develop novel nanovectors to deliver siRNA and miRNA based therapeutics as well as smallmolecule therapeutics As PI or coInvestigator on several previous NIH and DODfunded grants I laid the groundwork for the proposed research by developing antiCD44nanovectors that can target up to 66 cancer stem cells in vivo in a pancreatic tumor model and by establishing a collaborative network of experts in cancer stem cells miRNA and nanotechnology In addition I successfully administered the projects eg staffing research protections budget collaborated with other researchers and produced several peerreviewed publications from each project As a result of these previous experiences I am aware of the importance of frequent communication among project members and of constructing a realistic research plan timeline and budget The current application builds logically on my prior work on nanovectors and I have chosen coinvestigators Drs Simeone and Liu who provide additional expertise in cancer stem cells and human primary tumor models In summary I have a demonstrated record of successful and productive research projects relevant to the current proposal and my expertise and experience have prepared me to lead the proposed project

Molecular therapy targeting cancer and cancer stem cells, cancer biology, drug discovery and drug/gene delivery.Funded by multiple NIH and DOD grants, my lab is working on molecularly targeted cancer therapy and chemo/radiosensitization by modulating cell death signaling pathways, autophagy and apoptosis. We are exploring microRNAs as novel targets for cancer and cancer stem cells. We are currently using novel nanotechnology to develop nanovectors targeting cancer cells for siRNA/miRNA-based novel cancer therapeutics. We are also developing nanovectors targeting cancer stem cells and exploring novel molecular therapy for cancer stem cells.

Associate Professor Dept of Pharmacology Experimental TherapeuticsUniversity of Maryland School of Medicine

Protein phosphorylation and coupled post-translational modifications, mechanisms of drug resistance and tumor metastasis, cancer stem cells, mouse models of prostate cancer

Qualified National Eligibility Test NET for Lecturer ship conducted by CSIRUGC New Delhi India 1990 Qualified NET for Junior Research Fellowship Lecturer ship conducted by CSIRUGC New Delhi India 1991Research Associate awarded by Indian Council of Medical Research ICMR 1997Research Associate awarded by Council for Scientific Industrial Research CSIR 1998The Corner Stone Club award in System Service Excellence

Developing Molecular Markers for Early Cancer Diagnosis and Targeted Therapy for Cancer Treatment

Associate Professor Department of Carcinogenesis Science Park Research Division The University of Texas MD Anderson Cancer Center Smithville TXAdjunct Associate Professor School of Pharmacy The University of Texas at Austin Austin TX

Cancer stem cells; prostate cancer; apoptosis

Currently I am Associate Professor for Research in the Department of Environmental Toxicology at the University of California in Davis USAI have received my MSc and PhD at the University of Duesseldorf in Germany in Molecular Biology and Biochemistry in 1996 I was trained in Experimental Toxicology at the Medical Institute of Environmental Hygiene at the HeinrichHeineUniversity Duesseldorf Germany In 1999 I certified as an Expert Toxicologist by the Society of Pharmacology and Toxicology in Germany In 2000 I joined the Department of Environmental Toxicology and Center for Health and the Environment at UC DavisThe interaction of AhR and RelB is also the focus of my research project investigating the contribution of environmental exposure for the development of breast cancer Recent papers are demonstrating that certain cytokines and chemokines especially IL8 together with RelB are significantly overexpressed in inflammatory type of breast cancer

Role of environmental toxicants like polycyclic aromatic hydrocarbons (PAHs) in the carcinogenic action of non-Hodgkin lymphoma (NHL). The long-term objective of this study is to achieve a better understanding of the mechanistic action of the development of lymphoma, which is responsible for a higher incidence of these cancer diseases in humans exposed to environmental risk factors like dioxins and polychlorinated biphenyls (PCBs). Focus of this study is the suppression of apoptosis and transcriptional regulation of relevant target genes in the inflammatory response through the Aryl hydrocarbon Receptor (AhR) and NF-kappaB.

Department of BioengineeringUniversity of Illinois at Chicago USA

Cancer Science

PhD Indian Institute of Science Bangalore IndiaPostdoctoral Fellow Department of Biochemistry Medical College of Wisconsin Milwaukee WI Research Associate Department of Pharmacology Baylor College of Medicine Houston TX

Role and regulation of cytochrome P450 in chemical carcinogenesis and chemical atherogenesis,Mechanisms of lung injury and inflammation by hyperoxia,Role of transcription factors in oxidative stress and cancer.

Dr Natarajan Raghunand is an Associate Professor of Radiology and Director of Translational Cancer Imaging in the College of Medicine at the University of Arizona Tucson He received a PhD in Chemical Engineering from Texas AM University in College Station Texas in 1994 Subsequently he pursued postdoctoral training at the Arizona Cancer Center in tumor physiology and noninvasive imaging modalities for assessing the tumor microenvironment He is a member of the International Society for Magnetic Resonance in Medicine ISMRM and the Society for Molecular Imaging SMI

Dr. Raghunand’s primary research interests lie in the development of Magnetic Resonance Imaging (MRI) contrast agents that are sensitive to low pH and oxidative stress, both of which are defining characteristics of the microenvironment of many solid tumors. He is interested in developing MRI biomarkers of tumor response to therapies, in both the pre-clinical and translational settings.

Our laboratory is interested in glutathione metabolism and its role in stressdefense carcinogenesis drugresistance radiationresistance insulinresistance and cellsignaling mechanisms Dr Singhal has over 2 decades of experience working with human tissues as well as multiple vertebrate animal models as evident from publications

Our research expertise is in: 1) Multi-drug resistance in cancer, 2) Role of non-ABC drug transporter, 3) Stress signaling and oxidative stress, 4) Radiation poisoning and liposomal delivery, and 5) mouse syngeneic and human xenografts model.

Dr BrittneyShea Herbert is currently an Associate Professor of Medical and Molecular Genetics and Pharmacology and Toxicology at the Indiana University School of Medicine a Member of the Indiana University IU Melvin and Bren Simon Cancer Center and a Member of the Center for Regenerative Biology and Medicine Dr Herbert obtained her B A and PhD degrees in Biological Sciences with a focus on nutrition and cancer from the University of Texas at Austin Dr Herbert then performed postdoctoral research on telomeres and telomerase under the tutelage of Drs Jerry Shay and Woodring Wright at The University of Texas Southwestern Medical Center at Dallas Department of Cell Biology Among Dr Herbert’s honors are a NASA Graduate Student Research Fellowship a Susan G Komen Breast Cancer Fellowship a DOD Breast Cancer Research Program Postdoctoral Fellowship and numerous grants awarded for research in breast cancer

Dr. Herbert’s current research interests are the role of telomeres and telomerase in aging and cancer, with particular interests in cancer progression, inherited breast cancers, novel cancer therapeutic agents as well as preclinical models for cancer research. One of the oligonucleotide telomerase inhibitors investigated by Dr. Herbert’s laboratory is currently in clinical trials for cancer, including a breast cancer clinical trial at the IU Simon Cancer Center.

Associate Professor of Pathology OncologyDirector of Surgical Pathology Moffitt Cancer Center Program Director Oncologic Surgical Pathology Fellowship USF Special interests: GYN and GU malignancies and Cytopathology

Cancer

Ruben Rene GonzalezPerez Associate Professor Department of Microbiology Biochemistry and Immunology Morehouse School of Medicine Atlanta GA He is an Associate Member of the Graduate Faculty Cancer Biology Morehouse School of Medicine and an Associate Scientist Vincent Center Reproduction Biology Massachusetts General Hospital MA USA He has received a PhD in Enzymology Microbiology from the University of Havana Havana Cuba and INSA Toulouse France in 19801985 He has completed his BA in Biochemistry in the University of Havana Havana Cuba 1973 He has been trained in the following Institutions: 19781979 Moscow Research Institute of Food Science Moscow URSS Enzymology; 19831985 INSA Toulouse France EnzymologyMicrobiology; 19881989 Immunoassay Center Havana Cuba Immunoassays; 19891990 Karolinska Inst Stockholm Sweden Immunoassays/Human Reproduction; 19901990 Univ of Oulu Oulu Finland Immunoassays/Human Reproduction; 19962000 Inst Mother Child Res Univ Chile Santiago Chile Reproductive Biology; 19981999 Univ Geneva Geneva Switzerland Reproductive Biology; 1998 Univ Bologna Bologna Italy Gamete cryopreservation;19981999 Univ Valencia IVIValencia Valencia Spain Reproductive Biology; 1999 IVIMadrid Madrid Spain IVF and ICSI technologies; 20002001 Boston Biomedical Research Institute Watertown MA Proteomics/Cytokine Signaling in Cancer and Reproductive Immunology He is a Distinguished Cancer Scholar of the Georgia Cancer Coalition Atlanta GA 2008 His research has been funded by the Komen Foundation for the Cure The Cancer Research and Prevention Foundation CONRADCICCR The Breast Cancer Spore Program Univ of Alabama in Birmingham AL and NIH/NCI He is serving as an editorial board member of reputed journals and reviewer of 15 peerreviewed journals He has several patents and publications in the fields of cancer and reproductive biology

Cancer Biology,Reproductive Immunology

John A Dmacr;Orazio is an Assistant Professor of Pediatrics at the University of Kentucky College of Medicine A physician scientist by training Dr Dacute;Orazio specializes in the clinical care of children with cancer and blood disorders He received an MD and PhD in Microbiology and Immunology from the University of Miami School of Medicine His pediatric training 19961999 was done at the Massachusetts General Hospital Boston MA where he also served as Chief Resident in Pediatrics 19992000 He then joined the Pediatric HematologyOncology fellowship at DanaFarber Cancer Institute and Boston Children’s Hospital Boston MA after which he served as an Instructor of Pediatrics while completing a postdoctoral fellowship in the laboratory of Dr David Fisher DanaFarber Cancer Institute Dr Dacute;Orazio then joined the faculty of the University of Kentucky College of Medicine in 2004 and has established an independent research program there He has received numerous teaching and research awards

Mechanisms of melanoma development,Physiologic consequences of UV exposure in the skin,Role of the melanocortin 1 receptor (Mc1r) in DNA repair in melanocytes,Cancer predisposition syndromes,Immunodeficiency and cancer,General Pediatric Oncology

Mechanisms of melanoma developmentPhysiologic consequences of UV exposure in the skinRole of the melanocortin 1 receptor Mc1r in DNA repair in melanocytesCancer predisposition syndromesImmunodeficiency and cancerGeneral Pediatric Oncology

Chendil Damodaran is an Assistant professor, in Department of clinical sciences, college of Health Sciences, University of Kentucky in Lexington. He has received a PhD in Environmental toxicology, with specialized in Cancer biology at University of Madras, India in 1995. Dr. Damodaran received numerous honors including the Wethington Award of Excellence in Research, Semien´s Westinghouse competition Mentor Award and Monbusho scholarship award, etc. He is serving as a reviewer of more than 20 journals and he has published more than 30 papers in peer-reviewed journals.

Dr Andra Frost obtained her undergraduate degree in liberal arts from the University of Tennessee and a MD degree from the University of Alabama at Birmingham UAB in 1985 This was followed by residency training in Anatomic and Clinical Pathology and a combined Surgical Pathology and Cytopathology Fellowship at the George Washington UniversityShe was a faculty member of the Departments of Pathology at Georgetown University and George Washington University before joining the faculty at UAB in 1997 where she is currently an Associate Professor of Pathology and Cell Biology She was section head of the UAB Cytopathology Service from 1998 to 2001 and now participates in the Autopsy and Cytopathology Clinical Services Dr Frost’s research interest is primarily in breast cancer Earlier in her career her research focus was on the histologic and cytologic classification and prognostication of breast cancer Through this work she developed an interest in the stromal or desmoplastic response in breast cancer and has built a laboratory based research program in stromalepithelial interactions in breast cancer development and progression Current research projects involve Hedgehog signaling Glimediated transcription and primary cilia in breast cancer including their functions in the interactions between breast epithelial cells and fibroblasts She is also involved in collaborative projects to study KLF4 Notch metastasis suppressors and IGF1R in breast cancer Her work has been funded by the American Cancer Society the Department of Defense the Susan G Komen Foundation and NIH She was also Director of the UAB Laser Microdissection Facility from 1999 – 2009

The research of Dr. Frost’s laboratory is focused on understanding the effects of the stromal microenvironment of the breast on breast carcinogenesis and the progression of breast cancer, with the ultimate goal of identifying new targets for the prevention of invasive and metastatic disease. Current work includes the study of the role of Hedgehog signaling and Gli-mediated transcription in breast cancer, in both epithelial cells and fibroblasts. Because primary cilia are important in Hedgehog signaling, the presence and function of primary cilia in breast cancer and normal breast is also a topic of current interest.

Ignacio Durán MD PhD is the Associate Director of Clinical Research at START Madrid in Madrid Spain He is also the Coordinator of Teaching and Urogenital Tumors Programs at the Centro Integral Oncológico Clara Campal CIOCC in Madrid Spain and Professor at the School of Medicine of Universidad San Pablo CEU MadridSpainHe earned his MD in 1997 at the Universidad de Salamanca in Salamanca Spain and his PhD in 2005 at the Universidad Complutense in Madrid Spain with highest commendationHe trained in Medical Oncology at the Hospital Universitario Son Dureta in Palma de Mallorca Spain and completed his Fellowship in Drug Development at the Princess Margaret Hospital in Toronto Canada Throughout his career Dr Duran has spent significant time in distinguished national and international investigational centers such as the headquarters of the CSIC at the Universidad de Salamanca in Salamanca Spain Catholic University of the Sacred Heart in Rome Italy Centre Hospitalier Universitaire in Nantes France and Memorial Sloan Kettering Cancer Center in New York City NY

Dr. Duran’s major interests are genitourinary tumors, neuroendocrine tumors, and anticancer clinical drug development.

Gabriella Calviello is an Associate Professor of General Pathology at Catholic University Faculty of Medicine Rome ItalyShe earned the Magistral Degree in Biological Science in 1978 La Sapienza University Rome Italy and the title of Specialist in General Pathology in 1985 Catholic University Rome ItalyShe completed a Postdoctoral Fellowship at Catholic University Rome Italy in 1984 and in Basel Switzerland Cardiovascular Research CIBA GEIGY in 1988She was Assistant Professor at Institute of General Pathology Catholic University Rome Italy from 1985 to 1999She is member of the International Society for the Study of Fatty Acids and Lipids ISSFALShe is serving as an Editorial Board Member also for Nutrition an Metabolic Insight and as a reviewer for 23 reputed peerreviewed International JournalsShe is author of 69 papers published in International Journals with Impact Factor and of many book chapters She has been recently Editor of the book “Omega3 Fatty Acids and Cancer� Springer 2010

Anti-tumoral and anti-inflammatory effect of n-3 polyunsaturated fatty acids: molecular mechanisms involved. New methodologies for polyunsaturated fatty acid delivery in conjugation with antioxidants or other chemopreventive agents. Study of the effects of the new combined drugs in vitro and in vivo.

Associate Professor, Department of Urology, Dokkyo Medical University

Cancer Science

Major: Inflammogenesis of tumors Small animal tumor imaging PET MRI SPECT Optical imaging Tumor animal models focus on malignant melanoma Radiotherapy targeted radionuclide therapy Radiationinduced vascular dysfunctionMinor Metabolic Syndrome Atherosclerosis Inflammatory diseases Metabolic Syndrome and cancer risk Radioprotection

Oncology basic research / Biochemistry of malignant tumors / radiation biology / Clinical metabolic research

1986 MD Kawasaki Medical School Okayama Japan19861988 Internal Medicine Residency Kosei General Hospital Tokyo Japan1988 Instructor of Pathology Nippon Medical School Tokyo Japan 1994 PhD Nippon Medical School19951998 Postdoctoral Research fellow Department of Medicine Biological Chemistry and Pharmacology at the University of California in Irvine USA Prof Murray Korc 2000 Assistant Professor Department of Pathology Nippon Medical School2004 Associate Professor Department of Pathology Nippon Medical School

Pancreatic Cancer,Cancer stem cells,Growth factor and growth factor receptors,Proteoglycan

Guest professorsCapital University of Medical Science Beijing China, Henan Medical University Zheng zhou China Guizhou Medical University Guizhou China Invited dissertation as committee member Elina Sandwall licentiate Uppsala University 2007 1108 Tamanna Mustafiz half control Karolinska Institutet 2009 0205 Yu Wenfeng PhD Karolinska Institute 2006 0427Audur Magnusdottir PhD Stockholm University 2008 1114 Invited speakers in countries such as Singapore,China, USA, Spain, Austria and France.

To determine how neurofibrillary, degeneration is generated in normal brain aging and deteriorated in pathological brain aging such as Alzheimer disease,To determine the common molecular mechanisms between glioblastomas (GBMs) and Alzheimer disease.

Dr Satomi Onoue is the associate professor in Department of Pharmacokinetics and Pharmacodynamics School of Pharmaceutical Sciences University of Shizuoka Japan He earned his PhD at University of Shizuoka Shizuoka Japan He has published 85 peerreviewed papers and he was author of 3 book chapters He worked at Pfizer global research and development and he got 23 patents on new drug candidates DDS and research tools

(1) Development of peptide-based drug candidates for treatment of asthma/COPD, dry eye, and diabetes; (2) Design of dry powder inhalation system for pulmonary administration of peptides; and (3) Development of novel analytical tools for predicting drug-induced phototoxicity of pharmaceutical substances.

Dr Hofseth is an Associate Professor in the Department of Pharmaceutical and Biomedical Sciences at the South Carolina College of Pharmacy University of South Carolina Overall his research interests revolve around chronic inflammation and cancer Chronic inflammation is dangerous to human health It drives many prevalent diseases in our society including heart disease diabetes Alzheimerrsquo;s and cancer Current treatment strategies to dampen signs and symptoms of chronic inflammation are limited and fraught with sideeffects Dr Hofseth has dedicated his career to identifying novel targets and therapeutic approaches to suppressing inflammation with minimal toxicity One way is through the use of common complementary and alternative medicines that have antiinflammatory properties Another way is to team up with biochemists who synthesize small molecule inhibitors of specific proinflammatory molecules Dr Hofseth also carryies out clinical trials to examine the role of antioxidants in suppressing systemic inflammation and improve overall health Our benchtobedside approach will have farreaching health implications on millions of people suffering from autoimmune and chronic inflammatory diseases Dr Hofseth has published over 50 times in peerreviewed journals

Chronic inflammation and cancer,Complementary and Alternative Medicine, Targeting Peptidylarginine Deiminases to suppress colitis and colon cancer, Targeting Sphingosine Kinases to suppress colitis and colon cancer,Inflammatory load and human health

Dr LiMei Chen received her MD from Hunan Medical University in 1986 and her PhD in Biochemistry and Molecular Biology from Medical University of South Carolina in 1997 Currently she is working as a cancer researcher in University of Central Florida College of Medicine in the Department of Molecular Biology and Microbiology She has coauthored over 40 peerreviewed research articles and served as a reviewer or an editor for biomedical journals She is a member of the Society for Basic Urologic Research since 2005

Her research areas of interest include epithelial tight junctions and signal transduction, developmental biology, inflammation, cardiovascular biology and cancer biology.

Dr Bai obtained his PhD from Columbia University in 1996 with Dr Larry Chasin and his postdoctoral training was with Dr Giuseppe Attardi at Caltech Dr Bai started his own lab at the University of Texas Health Science Center at San Antonio in 2001 and now he is a tenured associate professor in the department of Cellular and Structural Biology there He is also an adjunct professor at Wenzhou Medical College in China Over the years Dr Bai has trained 6 postdoctoral fellows and more than 10 graduate students both at UT and WMC He has served in the review panels for NIH AHA UMDF MRC Welcome Trust and other funding agencies and reviewed manuscripts for more than 30 scientific journals

Aging Research - Mitochondrial DNA mutations and mitochondrial dysfunction in aging.Cancer Biology - Mitochondrial DNA mutations and mitochondrial dysfunction mediated signal transduction in cancer. Mitochondrial Molecular Biology - Revisiting basic questions in mitochondrial biology. Molecular Medicine - Restoration of mitochondrial function in cells with mitochondrial deficiency.

After getting his PhD degree at University of Maryland School of Medicine Human Genetics Program in 1998 he joined the research fellow at National Institutes of Health where he trained cancer biology and pharmacology During his fellow Dr Baek found a protein NAG1 induced by nonsteroidal antiinflammatory drugs which are known chemopreventive drugs in colorectal cancer Dr Baek joined the faculty of The University of Tennessee College of Veterinary Medicine and pioneered defining the critical target genes in chemoprevention and understanding how anticancer compounds act upon these genes to influence cancer prevention or development Several chemopreventive target genes were identified and characterized in his laboratory including activating transcription factor ATF3 early growth response EGR1 NSAID activated gene NAG1 and other tumor suppressor proteins Interestingly these proteins were also induced by several dietary compounds and PPAR? ligands supporting their role in anticancer antiobesity and antiinflammation activities His findings have important consequences in the development of new drugs for the prevention of cancer since it may be possible to develop drugs that selectively increase NAG1 and others in tumors and they provide a mechanistic explanation for preventing tumor development He is currently an Associate Professor at The University of Tennessee College of Veterinary Medicine and has published more than 70 manuscripts on the molecular targets of several chemopreventive compounds including phytochemicals PPAR? ligands and NSAIDs on colorectal tumorigenesis

Transcriptional regulation of apoptotic genes,Chemopreventive study using animal models,Post-translational regulation affected by chemopreventive compounds, with respect to Colorectal cancer prevention, ,Anti-obesity,Anti-inflammation.

Dr. Hsueh completed his doctorate in Medicine at Taipei Medical University in 1986, and doctorate in Pharmacology at Roswell Park Graduate Division, State University of New York at Buffalo in 1993. He completed Medical Oncology/Hematology fellowship at Memorial Sloan-Kettering Cancer Center in 1999. He has received fellowship and grant support from National Cancer Institute (U.S.A.), American Association for Cancer Research, National Science Council (Taiwan) and Celgene for conducting translational research and new drug development in aerodigestive malignancy. He was director of Clinical Pharmacology Laboratory in China Medical University Hospital, Taiwan. Dr. Hsueh currently is associate professor of Medicine, chair of Clinical Research Oversight Committee, and medical director of Centers of Excellence-Gastrointestinal and Head/Neck Cancers at Loma Linda University Cancer Center. He has coauthorized more than 60 journal publications, book chapters and meeting abstracts. He is associate editor of Journal of Hematology and Oncology, and serves as journal referee for Biochemical Pharmacology, Molecular Cancer, Cancer Investigation, Journal of the Pancreas and Cancer Chemotherapy & Pharmacology.

Translational research and new drug development in aerodigestive malignancy

Daotai Nie is the Associate Professor in Molecular Oncology Southern Illinois University School of Medicine and is a member in Southern Illinois University Simmons Cancer Institute He received his PhD degree from the University of South Carolina at Columbia SC in 1997

Major research interests include bioactive lipid signaling in tumor growth, progression and metastasis, drug resistance, and cancer stem cells. Cancer stem cells Lipid regulation of tumor growth and metastasis Mitochondrial defects in cancer Drug metabolism, disposition, and multi-drug resistance

MS degree in Biochemical Pharmacology/Toxicology from Sun YatSen University ChinaM D degree from Guangdong Medical and Pharmaceutical College ChinaPh D degree in Cancer Pharmacology from Kagoshima University School of Medicine JapanPostdoctoral training at Kagoshima University JapanPostdoctoral training in the Department of Medical Oncology Fox Chase Cancer Center Philadelphia Assistant professor at St John’s in 2004Associate professor at St John’s in 2008My research efforts have been in Cancer Pharmacology and Experimental Therapeutics especially focusing on cellular mechanisms of multidrug resistance MDR I have been involved in the research of most of the multidrug resistance proteins MRPs and have published ~60 publications in peerreviewed Journals for the last 10 years I teach Biochemistry Pharmacology Oncology at St John’s University I am a reviewer of 33 journals including International Journals and an editorial board member of 10 journals

My laboratory is interested in the molecular and cellular pharmacology of anticancer drugs, such as drug resistance mechanisms and reversal of resistance study and new drug development.A promise of our research program is that progress in the chemotherapy of cancer will depend on rational combination of agents that reduce the function of plasma membrane transporters (ATP-binding cassette trasnporters) such as P-gp, ABCG2 and MRPs, and to enhance the actions of cytotoxic drugs. In collaboration with many researchers in USA, China, Japan, Australia and Egypt, studies in our laboratory focus on screening and identifying new inhibitors of ABC transporters by in vitro membrane vesicles transport assay system and cell based assay systems. Another future research direction is to study the role of MRP family on the detoxification of chemicals using knock out mouse models.

Dan A Dixon PhD is an Associate Professor of Biological Sciences at the College of Arts Sciences University of South Carolina Columbia South CarolinaAssociate Director of the Center for Colon Cancer Research University of South CarolinaSenior Scientific Member at the University of South Carolina Cancer Research CenterHe received a PhD in molecular biology and biochemistry from Northwestern University Medical Center in Chicago IL in 1994He completed a postdoctoral fellowship in the Program in Human Molecular Biology Genetics at the University of Utah Salt Lake City UT in 1998He was a Research Assistant Professor in the Section of Surgical Sciences Division of Surgical Oncology at Vanderbilt University Medical Center NashvilleTN from 20012003He is a member of the American Association for Cancer Research and American Gastroenterological Association

Gene expression in cancer and chronic inflammation Post-transcriptional gene regulation,Cyclooxygenase and prostaglandin regulation.

Dr Basnakian received his MD degree from Sechenov Moscow Medical Academy and the PhD and Doctor of Sciencesdegrees from Russian Academy of Medical Sciences Both of his dissertations were in Biochemistry in the field of DNA endonucleases He then specialized in Toxicology and Cancer Research first in 198889 while being a postdoc at Boston Biomedical Research Institute and then in 199294 at the National Center for Toxicological Research in Jefferson Arkansas Dr Basnakian is now a tenured Associate Professor at the Department of Pharmacology and Toxicology at University of Arkansas for Medical Sciences His major area of expertise remains cytotoxic DNA endonucleases in tissue injury and cancer He is an author of 70 peerreviewed articles and numerous reviews and a member of NIH VA and AHA Study Sections

Mechanisms of tissue injury, cell death, apoptosis,DNA breaks, DNA fragmentation, TUNEL,Anti-cancer drugs, Histochemistry and immunocytochemistry, DNA damage and repair,Translational research

I am originally from Iowa and attended Iowa State University where I received a BS degree in Biochemistry Following that I then received my PhD degree in Biochemistry from The University of South Dakota School of Medicine The focus of my doctorate studies was DNA repair studies in Chlamydomonas rheinhardi I next completed two postdoctoral positions at Mt Sinai School of Medicine in New York City working first with Dr David Calhoun in Microbiology and then Dr Phyllis Shaw in Anatomy/Cell Biology I am currently an associate professor of Biochemistry at AT Still University in Kirksville Missouri I work with metastatic melanoma cells and am particularly interested in mechanisms of tumor cell migration and invasion by proteolytic enzymes

I am also interested in apoptosis, cell signaling, and mechanisms of cell aging.

Dr Grant received his BSc Honours from the University of Toronto with majors in Biochemistry and Chemistry and a minor in Zoology He then received his PhD in Medical Genetics from the University of Toronto School of Medicine and the Toronto Hospital for Sick Children Research Institute After a Postdoctoral Fellowship at the Roswell Park Cancer Institute in Buffalo he joined the Biomedical Sciences Division of the Lawrence Livermore National Laboratory in California After a Clinical Fellowship at the University of California San Francisco he moved to his present position at the University of Pittsburgh He has been Boardcertified in Clinical Molecular Genetics since 1993

Dr. Grant studies mechanisms of genetic and epigenetic alteration in cancer and other diseases of aging.

Dr J T Efird completed his Doctorate in Epidemiology Biostatistics Concentration at Stanford University School of Medicine He currently is an Associate Professor in the Department of Public Health Brody School of Medicine East Carolina University ECU and has a joint appointment as Epidemiologist/Chief Statistician in the Center for Health Disparities Research Prior to joining ECU Dr Efird was Director of the Biostatistics Facility at the John A Burns School of Medicine Honolulu Hawaii and an Associate Member of the Cancer Research Center of Hawaii

Dr. Efird’s research interests include brain tumours, soft-tissue sarcomas, and HPV-related cancers

The proposed research has five major goals One is to confirm preliminary data indicating dramatic deficiency in expression of DNA repair proteins ERCC1 and Pms2 as frequent early events forming large field defects in progression to colon cancer in humans A second goal is to characterize the mechanisms by which the ERCC1 and/or Pms2 deficiencies arise A third goal is to determine the mechanistic consequences of ERCC1 and/or Pms2 deficienciesA fourth goal is to characterize our new unique dietaryrelated wildtype mouse model of colon cancer to relate it to progression to colon cancer in humans A fifth goal is to use this mouse model to determine the protective effects of dietary caffeic acid resveratrol phenethyl isothiocyanate PEITC found in cruciferous vegetables and curcumin in prevention of colon cancerI have long term demonstrated expertise and motivation to carry out the proposed work As early as 1991 using deoxycholate and Chinese hamster ovary cells deficient in ERCC1 mutant cells UV4 I proposed that bile acids have an etiologic role in colon cancer by causing DNA damage Since then I have been first author or coauthor on 41 additional articles on the roles of bile acids field defects and DNA repair enzymes in colon carcinogenesis as well as use of bile acids in mouse models of inflammation Barrett’s esophagus and promotion of colonic adenomas The current application builds logically on my prior work and my physician coPI is a research oriented physician scientist who is actively involved in elucidating factors involved in progression to colon cancer

DNA damage in initiation and progression to cancer,DNA repair in initiation and progression to cancer, Bile acids as an endogenous carcinogen,Diet in relation to cancer

Chendil Damodaran is an Assistant professor in Department of clinical sciences college of Health Sciences University of Kentucky in Lexington He has received a PhD in Environmental toxicology with specialized in Cancer biology at University of Madras India in 1995 Dr Damodaran received numerous honors including the Wethington Award of Excellence in Research Semienacute;s Westinghouse competition Mentor Award and Monbusho scholarship award etc He is serving as a reviewer of more than 20 journals and he has published more than 30 papers in peerreviewed journals

Signal transduction pathways,Chemoprevention,Drug discovery,Molecular biology of prostate, breast and colon cancer.

Dr Nancy D Turner is an Associate Professor in the Department of Nutrition Food Science at Texas AM University and Past Chair of the Intercollegiate Faculty of Nutrition She also is a member of the Intercollegiate Faculty of Toxicology Intercollegiate Faculty of Genetics and Intercollegiate Faculty of Food Science She earned her PhD in Nutrition from Texas AM University in 1995 at which time she started a research program focusing on the area of diet and colon cancer prevention Most of the work conducted since that time has addressed the role of dietary fiber and the bioactive molecules in fibercontaining foods on mitigation of various aspects of colon carcinogenesis and inflammatory bowel disease Current research is designed to understand how the antioxidants polyphenols present in various foods influence the intestinal environment with particular attention to the interaction between the microbiota and the colon epithelia The disease initiators/promoters used in her studies have included chemical carcinogens galactic cosmic radiation Brookhaven National Laboratory and proinflammatory agents Her research has led to the publication of over 53 peerreviewed papers and book chapters and she was one of the editors for a book entitled “Potential Health Benefits of Citrus� She has been a reviewer for numerous journals served on the editorial board for the American Journal of Animal Science and has been an Associate Editor of ASN Nutrition Notes since 2000 Dr Turner has been a member of USDA/NRI and NSBRI review panels and an ad hoc member of the NCI Chemo/Dietary Prevention study section She has also served as a member of the National Space Biomedical Research Institute Teaching Advisory Board and the NASA Antioxidant Working Group

Dr. Turners research program focuses on determining the impact of dietary constituents on regulatory processes that may protect against carcinogenesis and inflammation in the colon. Her lab is evaluating the effects of fiber sources and the specific phytochemicals contained within them on aspects of cellular proliferation or apoptosis, and microbial/epithelial cell interactions. The goal is to determine how these normal processes are being perturbed by chemical carcinogens, radiation or pro-inflammatory compounds, and how diet may mitigate the damage caused by them. Work conducted in the laboratory is currently funded by the USDA/CSREES through the Texas A&M University Vegetable and Fruit Improvement Center, the USDA/ARS, and the National Space Biomedical Research Institute.

Masako Shimada is an Assistant Professor of Medicine Harvard Medical School She received a MD 1988 and a PhD in Medicine 1994 from Tokyo University Tokyo Japan She has authored 52 peerreviewed articles and 23 invited review articles and is serving as a reviewer of three journals

Structure and functional analysis of GPCR,Calpain biology,Cell cycle,Genetically-manipulated mouse models,Lipid metabolism,Obesity

Director and Associate Professor Department of Surgery Showa University FujigaokaHospitalYokohama20062008 Associate Professor Department of Surgery Showa University Fujigaoka Hospital Yokohama

Cancer Science

I have strong background in molecular carcinogenesis with specific training and expertise in several research areas My research focuses on 1 Understanding the role of oxidant stress in the pathogenesis of renal cell carcinoma 2 Screening cancer and diabetic patients for DNA repair gene mutations 3 Explore the mechanism of renal hypertrophy and fibrosis in diabetic patients 4 Study the mechanism by which TSC2 gene regulates the DNA damage 8oxodG and repair OGG1 pathways and other signal transduction including cell cycle proteins in the pathogenesis of renal carcinogenesis 5 study the role of tuberin/mTOR pathway in apoptosis in diabetes 6 Study the role of tuberin/mTOR pathway in the regulation of the neuronal damage in Alzheimers diseases AD and Parkinson diseases I am PI and coInvestigator on several previous and current projects funded by ADA NKF AHA VA and NIH Attesting to my national visibility I have been selected to serve as a regular reviewer for the Medical Research Program of the Department of Defense and Editorial Board Member of 2 Journals

Carcinogenesis in diabetes,Mutations in DNA repair gene in diabetes and cancer,Role of Tuberin in Neuronal Degeneration,Role of Tuberin in Renal Hypertrophy and Fibrosis,Role of Tuberin in Tumorigenesis,Role of tuberin/mTOR pathway in apoptosis.

Dr Hossam M Ashour was born in Cairo Egypt He got his BSc in Pharmaceutical Sciences at the Faculty of Pharmacy Cairo University Egypt He ranked the first in his class of a thousand students He was then appointed as Assistant Lecturer at the Department of Microbiology and Immunology Cairo University After spending two years at Cairo University and based on his accomplishments he was offered a graduate research fellowship at the University of Texas Southwestern in Dallas Texas USA Thus he joined University of Texas Southwestern Immunology program and got his MS degree in 2004 followed by his PhD in 2006 He was then appointed as a tenured faculty member at the Faculty of Pharmacy Cairo University Egypt After spending a year of research and teaching at Cairo University he was offered a research fellow position at the prestigious National Institutes of Health NIH in Bethesda Maryland After finishing his research fellowship he was offered an Assistant Professor position at Wayne State University in which he established an active research laboratory that he currently maintains Dr Ashour has remarkable highimpact publications and is a distinguished editorial board member and reviewer for many scientific journals He is also a member of the European Academy of Allergy and Clinical Immunology Society for Clinical and Translational Science SCTS Belgian Immunological Society the World Association of Medical Editors and other prominent organizations He has received numerous awards and has been invited to participate in various scientific conferences and workshops in the US Europe and Australia

Dr. Ashour’s research interests are in the areas of Microbiology and Immunology with emphasis on subjects that have broader impacts on human health and a particular focus on immune tolerance networks, Anterior Chamber Associated Immune Deviation (ACAID), and autoimmune Diseases.

Francisco Aguayo González is biochemist from University of Chile and received his PhD in Center for Viral Chronic diseases Division of Oncogenic and Persistent viruses Medicine Faculty Kagoshima University Japan He was studying viral factors associated with Human Cytomegalovirus HCMV pathogenicity and was studying the relationship between Human papillomavirus with extragenital cancer Now he is Assistant professor in the Virology program Medicine Faculty in University of Chile He is working about the relationship between persistent viral infections and cancer development Now he has a Grant supported by Fondecyt 11080198 to study the role of Human papillomavirus HPV and E6/E7 oncoproteins in lung cancer using clinical specimens and in vitro settings In addition he is interested in the role of HPV in other extragenital malignancies

Role of HPV in extragenital cancer Persistent viral infections

Osamu Hiraike belongs to the Department of Obstetrics and Gynecology Graduate School of Medicine The University of Tokyo Associate Professor of Graduate School of Medicine The University of Tokyo He has received a PhD in Medicine from the University of Tokyo Tokyo Japan in 20012002 He is serving as an editorial board member of reputed journals and reviewer of journals organs Fertility and treatment

Physiology of nuclear receptors and their ligands,Tumorigenesis dependent on hormones,Development of reproductive

Anupam Bishayee is an Assistant Professor of Pharmaceutical Sciences Northeastern Ohio Universities Colleges of Medicine and Pharmacy Rootstown OHHe has received a PhD in Pharmacy from Jadavpur University Calcutta India in 1996He has received a MPharm in Biochemistry from Jadavpur University Calcutta India in 1991 He received “Radiation Research Award� from Radiation Research Society in 2001 He received “Young Investigator Award� from IndoAmerican Society of Nuclear Medicine in 1999He is serving as an editorial board member of 4 reputed journals and reviewer of 17 journalsHe is an author of 61 articles 4 book chapters and presented more than 20 papers at national and international scientific meetings

Cancer chemoprevention and chemotherapy by dietary agents and phytochemicals
Chemoprevention of hepatocarcinogenesis and hepatocellular carcinoma Chemoprevention of mammary carcinogenesis and breast cancer Resveratrol and cancer chemoprevention Berry and cancer chemoprevention Oxidative stress, inflammation and cancer

Robert W Sobol Jr is an Assistant Professor in the Department of Pharmacology Chemical Biology and the Department of Human Genetics at the University of PittsburghHe is a scientific member of both the Molecular and Cellular Biology Program and the Brain Tumor Program at the University of Pittsburgh Cancer Institute UPCI Dr Sobol is the Director of the UPCI Lentiviral Facility and coDirector of the UPCI Vector Core Facility He received a PhD in Biochemistry from Temple University School of Medicine Philadelphia PA in 1991 He completed a BS in Chemistry from Allegheny College Meadville PA in 1982 Dr Sobol was awarded the Seth Harris Feldman Chair of Research in 2007 and 2008 and appointed as a Hillman Fellow for Innovative Cancer Research in 2010 for basic research on DNA Repair as potential therapeutic targets in brain cancer

Mechanisms of DNA repair,DNA Repair proteins as chemotherapy targets,Poly-(ADP)-ribose metabolism and catabolism,NAD metabolism in cancer,Relationship of DNA repair capacity and chemotherapy response

Sandra V Fernandez PhD is a Staff Scientist at Fox Chase Cancer Center PhiladelphiaPAShe has received her PhD in Molecular Biology from University of Buenos Aires Luis F Leloir Institute Buenos Aires Argentina in 1996She has completed her BS and MS in Biology in the University of Buenos Aires School of Sciences Buenos Aires Argentina in 1990She has 16 publications in prestigious journals She is a member of Ad hocScientific Review Panel of the New Jersey State Commission on Cancer Research NJCCR Seed grants and Postdoctoral FellowshipsShe is a member of Ad hocScientific Review Panel of The French National Research Agency Lmiddot;Agence Nationale de la Recherche FranceShe is ad hoc reviewer for 11 journalsShe is a member of the American Association for Cancer Research AACR and The Endocrine Society ENDO

Breast cancer.Hormonal carcinogenesis.Epigenetics. Toxicology.Clinical trials.Alcohol and cancer.

Anastasios Tassos Lymperopoulos BPharm MSc PhD came to Nova Southeastern University in August 2009 as Assistant Professor of Pharmaceutical Sciences Dr Lymperopoulos`s career as a biomedical researcher started by earning his MSc in Medicinal Chemistry followed by his PhD in Pharmacology after graduating from the School of Pharmacy of the University of Patras back in his home country Greece During his predoctoral career Dr Lymperopoulos focused his research on molecular pharmacology of drug receptors and more specifically on signal transduction of certain types of adrenergic receptors the molecules responsible for mediating the actions of adrenaline in the body

Cardiovascular biology/pharmacology and gene therapyStudy of mechanisms of adrenergic and other GPCR systems` regulation in heart failure and in ways of manipulating these mechanisms for therapeutic purposes. In particular, novel roles of G-protein coupled receptor kinases and their co-factors, beta-arrestins, in regulation of various important cardiovascular G-protein coupled receptors are investigated.

Daniel Ndisang is a Senior Research Scientist and Principal Investigator at the University College London Medical Schools where has been working in the field of childhood and gynaecological cancers for over a decade and a half now During this time he has not only collaborated internationally and setup national and international platforms for cancer research but most importantly he has made many breakthroughs particularly with regard to potential diagnostics prognostics treatment and management procedures for breast and cervical cancers In this essence he has made significant contributions in elucidating the role of transcription factors in breast and cervical cancers These significant findings have been published in peerreviewed journals like Oncogene Cancer Research Gynecologic Oncology Journal of Gynecological Cancer Journal of Clinical Investigation Journal of Biological Chemistry etcBesides his work has also been presented in national/international conferences and on news editorial and columns He is a reviewer for several journals including; Gynaecologic Oncology and open access journals like PLoS One and Journal of Experimental Clinical Cancer Research Editorial Dr Daniel Ndisang has also received several academic and scientific awards including the University College Hospital Medical School departmental scholarship to do a doctorate in molecular pathology in 1995 to 1998 and the Association for International Cancer Research prestigious research project grant to carry out research in gynaecological cancer in 2007 to 2010

Cancer Science

Abbott diagnostics Research Abbott Laboratories

Cancer Science

Department of DermatologyBaylor College of Medicine

Cancer Science

Department of Molecular and Regenerative Medicine HematologyOncology and Transfusion Medicine Center

Cancer Science

National Institute of Biomedical Innovation

Cancer Science

Q Quentin Li is a Senior Staff Biologist at the National Institutes of Health and was an Assistant Professor at the Mary Babb Randolph Cancer Center West Virginia University Robert C Byrd Health Sciences Center He was a Guest Professor/Visiting Professor for six reputed universities in China He obtained an MD from China and worked as Dermatologist at Sun YatSen University School of Medicine He also received his MS in Microbiology Immunology and PhD in Pharmacology and Experimental Therapeutics from the University of Maryland School of Medicine with postdoctoral training in Molecular and Cell Biology of Cancer in Medical Oncology Branch formerly Medicine Branch of the Center for Cancer Research at the National Cancer Institute He is a member of the American Association for Cancer Research He served as Principal Investigator on several grants funded by the National Institutes of Health and a pharmaceutical company He was elected to Who’s Who in Medicine and Healthcare Who’s Who in Science and Engineering Who’s Who in America and Who’s Who in the World in 2002 and 2003 He serves on the Editorial Board of two journals and is a reviewer for 14 scientific journals and a research development foundation He has authored over 80 peerreviewed research articles and reviews and presented more than 50 papers at national and international scientific meetings

Molecular & cell biology of cancer; Oncopharmacology & cancer chemotherapy; New anti-tumor drug research & development; Natural products as novel anti-cancer agents; Apoptosis & cell cycle control in cancer cells; DNA repair capacity & platinum drug resistance in human carcinomas; Epigenetic modulation of DNA damage responses and DNA repair; Identification of biomarkers and epigenetic markers for diagnosis and treatment of carcinomas; Epigenetic regulation of gene expression in T-cells and leukemic cells; Interface between angiogenesis and platinum sensitivity; Platinum and taxol drug resistance in lung cancer, ovarian cancer, bladder cancer, and other types of solid tumors.

Andrew Yeudall attended Glasgow University where he obtained degrees in Biochemistry 1983 and Dentistry 1986 Subsequently he was awarded a research training fellowship by the Medical Research Council He carried out studies at the Beatson Institute in the laboratory of Dr Saveria Campo investigating the possible association of human papillomaviruses with the etiology of oral cancer These studies led to the degree of PhD 1991In 1990 he was appointed as a lecturer in oral medicine and oral surgery at Bristol University after which he moved in 1993 as a visiting associate scientist to the laboratory of Dr Keith Robbins at the National Institutes of Health He held a visiting lectureship at the Eastman Dental Institute from 199598 and was appointed to positions of senior investigator 1999 and clinical senior lecturer 2001 at King’s College London In 2002 Dr Yeudall moved to Richmond Virginia as an associate professor of oral and craniofacial molecular biology in the Virginia Commonwealth University School of Dentistry He is also a member scientist in the VCU Massey Cancer Center and an associate professor of biochemistry Currently he is interim director of the VCU Philips Institute and interim chair of oral and craniofacial molecular biology In 2004 he was honored as a Visiting Professor in the Faculties of Dentistry at Thammasat Chulalongkorn and Chiang Mai Universities Dr Yeudall serves on the editorial board of Oral Oncology and as an ad hoc reviewer for a number of other journals in the fields of biochemistry and cancer research

Molecular and cellular biology of head and neck cancer metastasis, and identification of novel therapeutic targets for squamous cell carcinoma.